Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1982 Aug;43(2):730–736. doi: 10.1128/jvi.43.2.730-736.1982

Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.

D A Thorley-Lawson, C A Poodry
PMCID: PMC256176  PMID: 6287039

Abstract

The majority of hybridomas we have characterized against Epstein-Barr virions react with the major glycoproteins gp350 and gp220 (gp350/220). One of these antibodies, ID4C-1, neutralizes virus infection in vitro. The presence of gp350/220 on the viral envelope could be confirmed directly by immunoelectron microscopy. We used lectin affinity (ricin) and immunoaffinity (ID4C-1) to purify gp350/220 and show that this material is able to induce potent virus-neutralizing antibodies. Absorption of four human and one rabbit anti-Epstein-Barr virus sera with purified gp350/220 suggests that this is the primary component responsible for generating neutralizing antibodies in vivo.

Full text

PDF
732

Images in this article

731Image
on p.731
732Image
on p.732
733Image
on p.733

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Coope D., Heston L., Brandsma J., Miller G. Cross-neutralization of infectious mononucleosis and Burkitt lymphoma strains of Epstein-Barr virus with hyperimmune rabbit antisera. J Immunol. 1979 Jul;123(1):232–238. [PubMed] [Google Scholar]
  2. Dolyniuk M., Pritchett R., Kieff E. Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol. 1976 Mar;17(3):935–949. doi: 10.1128/jvi.17.3.935-949.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Edson C. M., Thorley-Lawson D. A. Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. J Virol. 1981 Jul;39(1):172–184. doi: 10.1128/jvi.39.1.172-184.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Kallin B., Luka J., Klein G. Immunochemical characterization of Epstein-Barr virus-associated early and late antigens in n-butyrate-treated P3HR-1 cells. J Virol. 1979 Dec;32(3):710–716. doi: 10.1128/jvi.32.3.710-716.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kessler S. W. Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol. 1975 Dec;115(6):1617–1624. [PubMed] [Google Scholar]
  7. Meuller-Lantzsch N., Georg B., Yamamoto N., zur Hausen H. Epstein-Barr virus-induced proteins. II. Analysis of surface polypeptides from EBV-producing and -superinfected cells by immunoprecipitation. Virology. 1980 Apr 30;102(2):401–411. doi: 10.1016/0042-6822(80)90107-5. [DOI] [PubMed] [Google Scholar]
  8. Misko I. S., Moss D. J., Pope J. H. HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4247–4250. doi: 10.1073/pnas.77.7.4247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. North J. R., Morgan A. J., Epstein M. A. Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. Int J Cancer. 1980 Aug;26(2):231–240. doi: 10.1002/ijc.2910260216. [DOI] [PubMed] [Google Scholar]
  10. Porath J., Axen R., Ernback S. Chemical coupling of proteins to agarose. Nature. 1967 Sep 30;215(5109):1491–1492. doi: 10.1038/2151491a0. [DOI] [PubMed] [Google Scholar]
  11. Qualtiere L. F., Pearson G. R. Epstein-Barr virus-induced membrane antigens: immunochemical characterization of Triton X-100 solubilized viral membrane antigens from EBV-superinfected Raji cells. Int J Cancer. 1979 Jun 15;23(6):808–817. doi: 10.1002/ijc.2910230612. [DOI] [PubMed] [Google Scholar]
  12. Robinson J. Assay for Epstein-Barr virus based on stimulation of DNA synthesis in mixed leukocytes from human umbilical cord blood. J Virol. 1975 May;15(5):1065–1072. doi: 10.1128/jvi.15.5.1065-1072.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schneeberger-Keeley E. E., Karnovsky M. J. The ultrastructural basis of alveolar-capillary membrane permeability to peroxidase used as a tracer. J Cell Biol. 1968 Jun;37(3):781–793. doi: 10.1083/jcb.37.3.781. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Silvestre D., Kourilsky F. M., Klein G., Yata Y., Neauport-Sautes C., Levy J. P. Relationship between the EBV-associated membrane antigen on Burkitt lymphoma cells and the viral envelope, demonstrated by immunoferritin labelling. Int J Cancer. 1971 Sep 15;8(2):222–233. doi: 10.1002/ijc.2910080206. [DOI] [PubMed] [Google Scholar]
  15. Strnad B. C., Neubauer R. H., Rabin H., Mazur R. A. Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. J Virol. 1979 Dec;32(3):885–894. doi: 10.1128/jvi.32.3.885-894.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Strnad B. C., Schuster T., Klein R., Hopkins R. F., 3rd, Witmer T., Neubauer R. H., Rabin H. Production and characterization of monoclonal antibodies against the Epstein-Barr virus membrane antigen. J Virol. 1982 Jan;41(1):258–264. doi: 10.1128/jvi.41.1.258-264.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sugawara K., Osato T. An immunoferritin study of a Burkitt lymphoma cell line harboring EB virus particles. Gan. 1970 Jun;61(3):279–281. [PubMed] [Google Scholar]
  18. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Thorley-Lawson D. A. Characterization of cross-reacting antigens on the Epstein-Barr virus envelope and plasma membranes of producer cells. Cell. 1979 Jan;16(1):33–42. doi: 10.1016/0092-8674(79)90185-5. [DOI] [PubMed] [Google Scholar]
  20. Thorley-Lawson D. A., Chess L., Strominger J. L. Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes. J Exp Med. 1977 Aug 1;146(2):495–508. doi: 10.1084/jem.146.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Thorley-Lawson D. A., Edson C. M. Polypeptides of the Epstein-Barr virus membrane antigen complex. J Virol. 1979 Nov;32(2):458–467. doi: 10.1128/jvi.32.2.458-467.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Thorley-Lawson D. A. The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon. J Immunol. 1981 Mar;126(3):829–833. [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES